Kaneko Motoki, Kanatani Yasuhiro, Sato Hirohiko, Sano Masaya, Teramura Erika, Imai Jin, Fujisawa Mia, Matsushima Masashi, Suzuki Hidekazu
Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan.
Department of Clinical Pharmacology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan.
J Clin Med. 2024 Feb 28;13(5):1392. doi: 10.3390/jcm13051392.
Ulcerative colitis (UC) has been associated with increased prostate cancer (PCa) risk. However, the mechanisms underlying UC and increased PCa risk remain unclear, and research on this topic is scarce in Japan. We have investigated whether UC is associated with PCa risk in the Japanese population and the risk factors related to PCa among older UC patients. This retrospective single-center cohort study was conducted between January 2010 and April 2022. A total of 68 cases were analyzed, and 9 cases of PCa were observed (13.2%). PCa occurred more frequently in the adult-onset group (8/40, 20.0%) than in the older-onset group with UC (1/28; 3.57%). No significant differences were observed between immunosuppressive therapies and PCa in patients, excluding those with pancolitis-type UC. PCa occurred more frequently in the pancolitis type, and the biologics group had no PCa cases, but the difference was not statistically significant ( = 0.07). This study suggests that pancolitis type and UC onset in middle-aged patients may be risk factors and found that biologics potentially suppress PCa development.
溃疡性结肠炎（UC）与前列腺癌（PCa）风险增加有关。然而，UC与PCa风险增加的潜在机制仍不清楚，且日本在这一主题上的研究较少。我们调查了在日本人群中UC是否与PCa风险相关，以及老年UC患者中与PCa相关的风险因素。这项回顾性单中心队列研究于2010年1月至2022年4月进行。共分析了68例病例，观察到9例PCa（13.2%）。PCa在成人发病组（8/40，20.0%）中比老年发病的UC组（1/28；3.57%）更频繁发生。在排除全结肠炎型UC患者的情况下，免疫抑制治疗与患者的PCa之间未观察到显著差异。PCa在全结肠炎型中更频繁发生，生物制剂组无PCa病例，但差异无统计学意义（P = 0.07）。本研究表明全结肠炎型和中年患者发生UC可能是风险因素，并发现生物制剂可能抑制PCa的发展。
